Microsoft Word - ASPA_0420_20120615_ASPR_PR_Countermeasures_Fact_Sheet_D_v02 - Update.docx - Aspa - Document - PDFSEARCH.IO

First Page		Document Content
Date: 2014-03-21 09:23:52 AstraZeneca Pharmaceutical industry Influenza vaccines Novartis Influenza MedImmune FluMist Influenza research Biomedical Advanced Research and Development Authority Vaccination Vaccines Medicine		Microsoft Word - ASPA_0420_20120615_ASPR_PR_Countermeasures_Fact_Sheet_D_v02 - Update.docx Add to Reading List Source URL: www.medicalcountermeasures.gov Download Document from Source Website File Size: 249,48 KB Share Document on Facebook

	One MedImmune Way Gaithersburg, MDTO: Immunization Provider or Awardee DocID: 1pDIX - View Document
	MedImmune and Tanabe Research Laboratories / Mitsubishi Tanabe Pharma Enter into Strategic Collaboration and Licensing Agreement for the Development of Pyrrolobenzodiazepine (PBD)-Based Antibody Drug Conjugates to Treat DocID: 1lU0o - View Document
	Green Registry 2015 Leadership Award Winner AstraZeneca/MedImmune n About AstraZeneca/MedImmune DocID: 1l9EK - View Document
	July 22, 2014 Advaxis and MedImmune Partner on Immuno-Oncology Combination Clinical Trial PRINCETON, N.J., July 22, 2014 (GLOBE NEWSWIRE) --Advaxis, Inc. DocID: 1jdz3 - View Document
	HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use SYNAGIS safely and effectively. See full prescribing information for SYNAGIS. SYNAGIS® (palivizumab) injection, for DocID: 1gqM3 - View Document